Cristina Hernándo

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Aleix Prat, Cristina Saura, Tomás Pascual et al. · The Lancet Oncology · 2019 · 191 citations

Breast Oncology, Medicine, Pharmacology +10

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

Sònia Pernas, Miguel Martín, Peter A. Kaufman et al. · The Lancet Oncology · 2018 · 133 citations

Breast Oncology, Oncology, Medicine +8

Small 6q16.1 Deletions Encompassing POU3F2 Cause Susceptibility to Obesity and Variable Developmental Delay with Intellectual Disability

Paul R. Kasher, Katherine E. Schertz, Megan Thomas et al. · The American Journal of Human Genetics · 2016 · 73 citations · Full text

Obesity, Metabolic Syndrome, Developmental Biology +7

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis

Begoña Jiménez Rodríguez, Gema Díaz Córdoba, Alicia Garrido Aranda et al. · Journal of Clinical Medicine · 2019 · 57 citations · Full text

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

E. Hamilton, Maila Dayane Capuchinho de Oliveira, Nicholas C. Turner et al. · Annals of Oncology · 2024 · 56 citations · Full text